Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening

CA Cancer Journal for Clinicians

Volumn 69, Issue 3, 2019, Pages 184-210

  Smith, Robert A ^a   Andrews, Kimberly S ^a   Brooks, Durado ^a   Fedewa, Stacey A ^a   Manassaram Baptiste, Deana ^a   Saslow, Debbie ^a   Wender, Richard C ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

breast neoplasms; cervical neoplasms; colon and rectum neoplasms; lung neoplasms; mass screening

Indexed keywords

WART VIRUS VACCINE;

ADENOMATOUS POLYP; AGE; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; EARLY CANCER DIAGNOSIS; ENDOMETRIUM CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUNG CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; MASS SCREENING; NON PROFIT ORGANIZATION;

AMERICAN CANCER SOCIETY; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 85063005450     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21557     Document Type: Article

References (162)

1. Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495-2499.
2. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012;62:129-142.
3. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141-169.
4. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
5. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-1614.
6. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
7. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
8. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
9. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30-54.
10. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016;66:375-385.
11. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67:100-121.
12. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early lung cancer detection. CA Cancer J Clin. 2001;51:38-75; quiz 77-80.
13. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53:44-55.
14. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin. 2006;56:160-167; quiz 185-166.
15. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56:143-159; quiz 184-145.
16. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130-160.
17. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250-281.
18. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
19. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107-117.
20. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68:297-316.
21. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844-857.
22. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758-768.e11.
23. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018.
24. Siegel R, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-35.
25. American Cancer Society. American Cancer Society Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019.
26. Miglioretti DL, Zhu W, Kerlikowske K, et al. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol. 2015;1:1069-1077.
27. US Census Bureau. Annual Estimates of the Resident Population by Singe Year of Age and Sex for the United States, States, and Puerto Rico Commonwealth: April 1, 2010 to July 1, 2017. 2017 Population Estimates. Suitland, MD: Population Division, US Census; 2018. factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2017_PEPANNRES&src=pt. Accessed November 9, 2018.
28. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314:1615-1634.
29. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA. 2012;307:182-192.
30. Lee S, Smith A, Widera E, Yourman L, Schonberg M, Ahalt C. ePrognosis—Estimating Prognosis for Elders. Portal of Geriatrics Online Education (POGOe); 2012. pogoe.org/productid/21148. Accessed September 29, 2015.
31. Walter LC, Schonberg MA. Screening mammography in older women: a review. JAMA. 2014;311:1336-1347.
32. Johns LE, Swerdlow AJ, Moss SM. Effect of population breast screening on breast cancer mortality to 2005 in England and Wales: a nested case-control study within a cohort of one million women. J Med Screen. 2018;25:76-81.
33. Broeders MJM, Allgood P, Duffy SW, et al. The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review [serial online]. BMC Cancer. 2018;18:860.
34. Tabar L, Chen TH, Yen AM, et al. Effect of mammography screening on mortality by histological grade. Cancer Epidemiol Biomarkers Prev. 2018;27:154-157.
35. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Breast Cancer Screening. IARC Handbooks of Cancer Prevention, Volume 15. Lyon, France: International Agency for Research on Cancer; 2016.
36. Autier P, Boniol M. Mammography screening: a major issue in medicine. Eur J Cancer. 2018;90:34-62.
37. Miller AB. The role of screening mammography in the era of modern breast cancer treatment. Climacteric. 2018;21:204-208.
38. Moss SM, Nystrom L, Jonsson H, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. J Med Screen. 2012;19(suppl 1):26-32.
39. Beau AB, Andersen PK, Vejborg I, Lynge E. Limitations in the effect of screening on breast cancer mortality. J Clin Oncol. 2018;36:2988-2994.
40. Tabar L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125:515-523.
41. Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260:658-663.
42. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer. 1999;85:2183-2189.
43. Duffy SW, Cuzick J, Tabar L, et al. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programs. Appl Stat. 2002;51:234-243.
44. Welch HG. Screening mammography—a long run for a short slide? N Engl J Med. 2010;363:1276-1278.
45. Graubard BI, Freedman AN, Gail MH. Five-year and lifetime risk of breast cancer among US subpopulations: implications for magnetic resonance imaging screening. Cancer Epidemiol Biomarkers Prev. 2010;19:2430-2436.
46. Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk [serial online]. J Natl Cancer Inst. 2015;107:djv124.
47. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. Cancer. 2008;113:3116-3120.
48. Ozanne EM, Drohan B, Bosinoff P, et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev. 2013;22:146-149.
49. Punglia RS, Hassett MJ. Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010;28:4108-4110.
50. Mulder RL, Kremer LC, Hudson MM, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2013;14:e621-e629.
51. Cintolo-Gonzalez JA, Braun D, Blackford AL, et al. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat. 2017;164:263-284.
52. Massad LS, Einstein MH, Huh WK, et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 suppl 1):S1-S27.
53. The American Society for Colposcopy and Cervical Pathology (ASCCP). ASCCP Risk-Based Management Consensus Guidelines. Frederick, MD: American Society for Colposcopy and Cervical Pathology; 2018. asccp.org/consensus-guidelines. Accessed November 9, 2018.
54. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136:178-182.
55. US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686.
56. Moyer VA. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891, W312.
57. US Preventive Services Task Force. Draft Recommendation Statement: Cervical Cancer: Screening. US Preventive Services Task Force. Rockville, MD: US Preventive Services Task Force; 2018. uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/cervical-cancer-screening2. Accessed November 9, 2018.
58. Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses [serial online]. BMJ. 2018;363:k4823.
59. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320:687-705.
60. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines [serial online]. J Natl Cancer Inst. 2015;107:djv086.
61. Centers for Disease Control and Prevention. HPV and Cancer. Atlanta, GA: Centers for Disease Control and Prevention; 2017. cdc.gov/cancer/hpv/statistics/cases.htm. Accessed December 5, 2017.
62. Centers for Disease Control and Prevention (CDC). Cancers Associated With Human Papillomavirus, United States—2011-2015. USCS Data Brief, No. 4. Atlanta, GA: Centers for Disease Control and Prevention; 2018.
63. Castle PE, Xie X, Xue X, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med. 2018;118:44-50.
64. Kim J, Bell C, Sun M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Can Med Assoc J. 2016;188:E281-E288.
65. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study [serial online]. BMC Med. 2013;11:227.
66. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia [serial online]. BMJ. 2014;348:g1458.
67. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405-1408.
68. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:909-917.
69. National HPV Vaccination Roundtable. National HPV Vaccination Roundtable Website. hpvroundtable.org/. Accessed December 19, 2017.
70. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177-193.
71. Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013 [serial online]. J Natl Cancer Inst. 2017;109:djw322.
72. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66:726-735.
73. Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970-2014. JAMA. 2017;318:572-574.
74. Meester RGS, Peterse EFP, Knudsen AB, et al. Optimizing colorectal cancer screening by race and sex: microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124:2974-2985.
75. Peterse EFP, Meester RGS, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124:2964-2973.
76. Volk RJ, Leal VB, Jacobs LE, et al. From guideline to practice: new shared decision-making tools for colorectal cancer screening from the American Cancer Society. CA Cancer J Clin. 2018;68:246-249.
77. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med. 2008;149:659-669.
78. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106-1114.
79. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81-85.
80. Bretthauer M, Kalager M, Weinberg DS. From colorectal cancer screening guidelines to headlines: beware! Ann Intern Med. 2018;169:405-406.
81. Imperiale TF, Kahi CJ, Rex DK. Lowering the starting age for colorectal cancer screening to 45 years: who will come…and should they? Clin Gastroenterol Hepatol. 2018;16:1541-1544.
82. Liang PS, Allison J, Ladabaum U, et al. Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years. Gastroenterology. 2018;155:950-954.
83. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302:1757-1764.
84. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2016 Sub (1975-2014) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
85. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2014) (underlying mortality data provided by the National Vital Statistics System, 2016). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2017.
86. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739-750.
87. Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156:378-386.
88. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307-323.
89. American Society for Gastrointestinal Endoscopy. Colorectal Cancer Screening. Downers Grove, IL: American Society for Gastrointestinal Endoscopy; 2018. asge.org/home/about-asge/newsroom/media-backgrounders-detail/colorectal-cancer-screening. Accessed November 17, 2018.
90. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315:2595-2609.
91. Joseph DA, Meester RG, Zauber AG, et al. Colorectal cancer screening: estimated future colonoscopy need and current volume and capacity. Cancer. 2016;122:2479-2486.
92. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564-2575.
93. Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2017;15:728-737.e3.
94. Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3:464-471.
95. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166-1169.
96. Scott RB, Rangel LE, Osler TM, Hyman NH. Rectal cancer in patients under the age of 50 years: the delayed diagnosis. Am J Surg. 2016;211:1014-1018.
97. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: benetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-262; quiz 263.
98. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101-1121.e1-e13.
99. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2014;147:502-526.
100. Leddin D, Lieberman DA, Tse F, et al. Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma: the Canadian Association of Gastroenterology Banff Consensus. Gastroenterology. 2018;155:1325-1347.e23.
101. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738-745.
102. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancer, Version 4.0–October 2013. Monrovia, CA: Children's Oncology Group; 2013. survivorshipguidelines.org/pdf/ltfuguidelines_40.pdf. Accessed November 23, 2018.
103. Hadjiliadis D, Khoruts A, Zauber AG, et al. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154:736-745.e14.
104. White PM, Sahu M, Poles MA, Francois F. Colorectal cancer screening of high-risk populations: a national survey of physicians [serial online]. BMC Res Notes. 2012;5:64.
105. Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216-224.
106. Skinner CS, Ahn C, Halm EA, et al. Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. Prev Med. 2017;102:20-23.
107. Lowery JT, Ahnen DJ, Schroy PC 3rd, et al. Understanding the contribution of family history to colorectal cancer risk and its clinical implications: a state-of-the-science review. Cancer. 2016;122:2633-2645.
108. Chubak J, Garcia MP, Burnett-Hartman AN, et al. Time to colonoscopy after positive fecal blood test in four US health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25:344-350.
109. May F, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17:469-476.
110. Lee YC, Fann JC, Chiang TH, et al. Time to colonoscopy and risk of colorectal cancer in patients with positive results from fecal immunochemical tests [published online ahead of print October 31, 2018]. Clin Gastroenterol Hepatol. doi: https://doi.org/10.1016/j.cgh.2018.10.041.
111. Lee YC, Li-Sheng Chen S, Ming-Fang Yen A, et al. Association between colorectal cancer mortality and gradient fecal hemoglobin concentration in colonoscopy noncompliers [serial online]. J Natl Cancer Inst. 2017;109:djw269.
112. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156:63-74.e6.
113. Selby K, Baumgartner C, Levin TR, et al. Interventions to improve follow-up of positive results on fecal blood tests: a systematic review. Ann Intern Med. 2017;167:565-575.
114. Meester RG, Doubeni CA, Zauber AG, et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015;121:2281-2285.
115. National Colorectal Cancer Roundtable. National Colorectal Cancer Roundtable Website. nccrt.org. Accessed August 21, 2018.
116. Centers for Disease Control and Prevention. The Behavioral Risk Factor Surveillance Survey. Atlanta, GA: National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health, Centers for Disease Control and Prevention; 2018. cdc.gov/brfss/index.html. Accessed March 2, 2018.
117. Wender RC, Doroshenk M, Brooks D, Hotz J, Smith RA. Creating and implementing a national public health campaign: the American Cancer Society's and National Colorectal Cancer Roundtable's 80% by 2018 Initiative. Am J Gastroenterol. 2018;113:1739-1741.
118. American Cancer Society. Testing for prostate cancer. In: American Cancer Society, ed. Atlanta, GA: American Cancer Society; 2017:1-16. cancer.org/content/dam/cancer-org/cancer-control/en/booklets-flyers/testing-for-prostate-cancer-handout.pdf. Accessed November 28, 2018.
119. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
120. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83:1362-1367.
121. Thompson IM Jr, Leach RJ, Ankerst DP. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA. 2014;312:995-996.
122. Vickers AJ, Eastham JA, Scardino PT, Lilja H. The Memorial Sloan Kettering Cancer Center recommendations for prostate cancer screening. Urology. 2016;91:12-18.
123. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
124. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
125. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455.
126. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:1901-1913.
127. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:1914-1931.
128. Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
129. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80-82.
130. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218.e1-e6.
131. Walker JL, Nunez ER. Endometrial cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: Marcel Dekker, Inc; 1999:531-566.
132. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
133. Moyer VA, US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-338.
134. Centers for Medicare & Medicaid Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). Baltimore, MD: Centers for Medicare & Medicaid Services, US Department of Health and Human Services; 2015. cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=5274. Accessed November 29, 2018.
135. Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 32018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:412-441.
136. International Association for the Study of Lung Cancer. NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men [press release]. Aurora, CO: International Association for the Study of Lung Cancer; 2018.
137. National Cancer Institute. Statement Concerning the Lung Cancer Screening Trial. Bethesda, MD: National Cancer Institute; 2010. cancer.gov/images/DSMB-NLST.pdf. Accessed November 29, 2018.
138. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99-105.
139. National Center for Health Statistics. National Health Interview Survey. Atlanta, GA: Centers for Disease Control and Prevention; 2018. cdc.gov/nchs/nhis/about_nhis.htm. Accessed November 23, 2018.
140. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3:1278-1281.
141. Modin HE, Fathi JT, Gilbert CR, et al. Pack-year cigarette smoking history for determination of lung cancer screening eligibility. Comparison of the electronic medical record versus a shared decision-making conversation. Ann Am Thorac Soc. 2017;14:1320-1325.
142. Cole AM, Pflugeisen B, Schwartz MR, Miller SC. Cross sectional study to assess the accuracy of electronic health record data to identify patients in need of lung cancer screening [serial online]. BMC Res Notes. 2018;11:14.
143. Drope J, Liber AC, Cahn Z, et al. Who's still smoking? Disparities in adult cigarette smoking prevalence in the United States. CA Cancer J Clin. 2018;68:106-115.
144. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:588-594.
145. Moyer VA, US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157:900-904.
146. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-340.
147. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945-956.
148. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295-2303.
149. Menon U, Ryan A, Kalsi J, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015;33:2062-2071.
150. Jacobs IJ, Parmar M, Skates SJ, Menon U. Ovarian cancer screening: UKCTOCS trial—authors' reply. Lancet. 2016;387:2603-2604.
151. Office of Disease Prevention and Health Promotion, US Department of Health and Human Services. Healthy People 2020. Washington, DC: US Department of Health and Human Services; 2018. healthypeople.gov. Accessed November 23, 2018.
152. Fedewa SA, Ward EM, Brawley O, Jemal A. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med. 2017;177:1040-1042.
153. Han PK, Kobrin S, Breen N, et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013;11:306-314.
154. Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009;169:1611-1618.
155. White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:201-206.
156. Cronin KA, Miglioretti DL, Krapcho M, et al. Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev. 2009;18:1699-1705.
157. Sauer AG, Liu B, Siegel RL, Jemal A, Fedewa SA. Comparing cancer screening estimates: Behavioral Risk Factor Surveillance System and National Health Interview Survey. Prev Med. 2018;106:94-100.
158. Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract. 2000;13:1-10.
159. Fenton JJ, Cai Y, Weiss NS, et al. Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med. 2007;167:580-585.
160. Murphy DR, Wu L, Thomas EJ, Forjuoh SN, Meyer AN, Singh H. Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial. J Clin Oncol. 2015;33:3560-3567.
161. Murphy DR, Meyer AND, Vaghani V, et al. Electronic triggers to identify delays in follow-up of mammography: harnessing the power of big data in health care. J Am Coll Radiol. 2018;15:287-295.
162. Halm EA, Beaber EF, McLerran D, et al. Association between primary care visits and colorectal cancer screening outcomes in the era of population health outreach. J Gen Intern Med. 2016;31:1190-1197.